Piper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10

Benzinga Newsdesk www.benzinga.com Positive 75.6%

Neg 0% Neu 0% Pos 75.6%

Piper Sandler analyst Matt O'Brien reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $9 to $10.